Research programme: cancer metabolism therapeutics - Agios Pharmaceuticals

Drug Profile

Research programme: cancer metabolism therapeutics - Agios Pharmaceuticals

Alternative Names: DHODH inhibitor - Agios Pharmaceuticals; Dihydrooroate dehydrogenase inhibitor - Agios Pharmaceuticals

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 15 Jan 2018 Preclinical development in Haematological malignancies in USA (unspecified route)
  • 15 Jan 2018 Agios Pharmaceuticals plans to file an IND application for dihydrooroate dehydrogenase inhibitor for haematological malignancies in the fourth quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top